1) allogeneic hematopoietic cell transplantation
异基因造血细胞移植
1.
The profound graft-versus-leukemia (GVL) effect presented after allogeneic hematopoietic cell transplantation (allo-HSCT) has been evidenced.
异基因造血细胞移植后 ,供体细胞所拥有的强大而持久的免疫治疗功效已越来越为人所熟知。
2) allogeneic hematopoietic stem cell transplantation
异基因造血干细胞移植
1.
Effect of donor CD4~+CD25~+ regulatory T cells on hematopoietic and immune reconstitution,GVHD and disease-free survival after allogeneic hematopoietic stem cell transplantation;
供者调控T细胞对异基因造血干细胞移植后造血与免疫重建、移植物抗宿主病发生及生存的影响
2.
Study on pulmonary complications occurrence and risk factor after allogeneic hematopoietic stem cell transplantation;
异基因造血干细胞移植后肺部并发症的发生和危险因素分析
3.
A tracking detection on chimerism after allogeneic hematopoietic stem cell transplantation;
异基因造血干细胞移植后嵌合状态的追踪监测
3) allo-HSCT
异基因造血干细胞移植
1.
To investigate the relationship between the plasma levels of chemokine CXCL9/Mig and acute graft- versus- host disease (aGVHD) after allogeneic hematopoietic stem cell transplantation(allo-HSCT).
研究血浆炎性趋化因子CXCL9/Mig在异基因造血干细胞移植(allo-HSCT)前后的水平变化,以探讨该因子在急性移植物抗宿主病(aGVHD)发病中的作用。
2.
This study was aimed to eveluate the role of CCR5 on donor cells in recipient models received intensive conditioning, so as provide the scientific evidence for clinical application of allo-HSCT.
本研究评价供者CCR5在经过强化预处理的骨髓移植动物模型受者体内的作用,为今后的异基因造血干细胞移植的临床应用提供科学依据。
3.
Objective To evaluate the role of gene CCR5 on donor cells in models where intensive preconditioning of the recipient occurs,thus provide the scientific evidence for clinical experience of allo-HSCT.
目的评价供者CCR5在经过强化预处理的骨髓移植动物模型受者体内的作用,为异基因造血干细胞移植的临床应用提供科学依据。
4) allogeneic stem cell transplantation
异基因造血干细胞移植
1.
Objective To explore the condition of cytomegalovirus(CMV) infection and interstitial pneumonia(IP) after allogeneic stem cell transplantation,and the effect of their prevention and treatment.
目的探讨异基因造血干细胞移植中巨细胞病毒(CMV)感染和间质性肺炎(IP)的预防和治疗。
2.
To establish a method for quantitative assessment of mixed hematopoietic chimerism by competitive polymerase chain reaction after nonmyeloablative allogeneic stem cell transplantation(NAST) using highly polymorphic short tandem repeats (STRs).
利用STRs的高度多态性等特性 ,用竞争性聚合酶链反应 (PCR)结合聚丙烯凝胶电泳、染色和凝胶成像分析等技术 ,建立定量检测异基因造血干细胞移植后供受者嵌合体的方法 ,用无关个体的DNA混合实验进行可行性和准确性研究 ,并同时做染色体分带进行对照。
3.
The author briefs the main research progress and way of the new developed nonmyeloablative allogeneic stem cell transplantation(NAST).
简述了国内外刚刚开展的非清髓异基因造血干细胞移植 (NAST)的主要研究进展和研究方向。
6) Allogeneic peripheral blood stem cell transplantation
异基因外周血造血干细胞移植
1.
The aim of study was to explore the incidence,risk factors,outcome and efficacious treatment of late-onset noninfectious pulmonary complications(LNIPC)after allogeneic peripheral blood stem cell transplantation(allo-PBSCT).
本研究探讨异基因外周血造血干细胞移植(allo-PBSCT)后迟发性非感染性肺部合并症(late-onset nonin-fectious pulmonary complications,LNIPC)的发生、危险因素、预后及治疗方法。
2.
Objective: To study the effect of allogeneic peripheral blood stem cell transplantation (PBSCT) with low dose pretreatment in chronic myelocytic leukemia (CML).
目的 探讨低预处理剂量异基因外周血造血干细胞移植 (allo -PBSCT)治疗慢性粒细胞白血病 (CML)的治疗效果。
3.
This study was purposed to investigate immune reconstitution at 12 months after allogeneic peripheral blood stem cell transplantation(all-PBSCT) and its relation with the influencing factors such as age,HLA compati-bility,graft versus host desease and viral infection.
为探讨异基因外周血造血干细胞移植(allo-PBSCT)后12个月内患者免疫重建特点及其与供受者年龄、供受者间HLA相容性、移植物抗宿主病(GVHD)及病毒感染的关系,随访37例异基因造血干细胞移植患者,用流式细胞术测定移植后1、3、6及12个月的T细胞亚群(CD3+、CD4+、CD8+)、B细胞(CD19+)及NK(CD16+CD56+)细胞,用散射比浊法检测免疫球蛋白IgG、IgA及IgM水平。
补充资料：造血细胞生长因子
分子式：
CAS号：
性质：足指一类促使造血干细胞分化的生长因子。如SCF，G-CSF，M-CSF，GM-CSF，EPO，TPO等。
CAS号：
性质：足指一类促使造血干细胞分化的生长因子。如SCF，G-CSF，M-CSF，GM-CSF，EPO，TPO等。
说明：补充资料仅用于学习参考，请勿用于其它任何用途。
参考词条